PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10842896-2 2000 Angiotensin II causes a variety of potentially noxious biological effects, such as vasoconstriction, a rise in blood pressure, release of aldosterone, enhancement of the effect of catecholamines, and vascular and myocardial hypertrophy, including remodeling of the heart after myocardial infarction. Catecholamines 180-194 angiotensinogen Homo sapiens 0-14 12609750-0 2003 Angiotensin II mediates catecholamine and neuropeptide Y secretion in human adrenal chromaffin cells through the AT1 receptor. Catecholamines 24-37 angiotensinogen Homo sapiens 0-14 12609750-1 2003 The aim of the present work was to study the effect of angiotensin II (Ang II) on catecholamines and neuropeptide Y (NPY) release in primary cultures of human adrenal chromaffin cells. Catecholamines 82-96 angiotensinogen Homo sapiens 55-69 12609750-1 2003 The aim of the present work was to study the effect of angiotensin II (Ang II) on catecholamines and neuropeptide Y (NPY) release in primary cultures of human adrenal chromaffin cells. Catecholamines 82-96 angiotensinogen Homo sapiens 71-77 15383007-1 2005 ANG II (angiotensin II) facilitates catecholamine release from the adrenal medulla and neuronal NE (noradrenaline) release. Catecholamines 36-49 angiotensinogen Homo sapiens 8-22 15549173-2 2004 Whereas there is evidence that Ang II may potentiate the effects of catecholamines, various cytokines and also growth factors, the repertoire of substances which may inhibit the actions of Ang II is more limited and has been restricted primarily to prostacyclin, bradykinin and nitric oxide. Catecholamines 68-82 angiotensinogen Homo sapiens 31-37 9124547-1 1997 An important facilitating effect of angiotensin II on adrenal catecholamine release has been demonstrated in several species. Catecholamines 62-75 angiotensinogen Homo sapiens 36-50 10361444-1 1999 Angiotensin II (AII), the effector octapeptide of the renin-angiotensin system, exerts a multitude of actions, including vascular contraction, aldosterone secretion, catecholamine release, glycogenolysis, and decreased renal filtration. Catecholamines 166-179 angiotensinogen Homo sapiens 0-14 10361444-1 1999 Angiotensin II (AII), the effector octapeptide of the renin-angiotensin system, exerts a multitude of actions, including vascular contraction, aldosterone secretion, catecholamine release, glycogenolysis, and decreased renal filtration. Catecholamines 166-179 angiotensinogen Homo sapiens 16-19 8682056-3 1995 Although not entirely elucidated, injury follows Ang II-associated release of adrenal medullary catecholamines and aldosterone-induced myocardial potassium depletion. Catecholamines 96-110 angiotensinogen Homo sapiens 49-55 9275755-7 1997 We did not prove an association between BP and polymorphism of ACE and angiotensinogen genes, however, our findings of association of DD genotype for ACE and M235 for angiotensinogen with higher insulinemia, plasma catecholamines and plasma renin activity evoke the hypothesis, whether the bearers of these genotypes, exposed for long-time to the higher concentrations of vascoactive substances, are not the subset of hereditary threatened subjects in whom clinically evident EH will manifest during their life. Catecholamines 215-229 angiotensinogen Homo sapiens 167-182 8640982-2 1996 Long-term nitroglycerin infusion is associated with increases in plasma renin activity and catecholamine release rates, both of which may lead to excess angiotensin II and alpha-adrenergic-mediated vasoconstriction, particularly on withdrawal of nitroglycerin. Catecholamines 91-104 angiotensinogen Homo sapiens 153-167 7735274-0 1995 Interactions of angiotensin II with central catecholamines. Catecholamines 44-58 angiotensinogen Homo sapiens 16-30 7503249-0 1995 Catecholamine response to chronic ANG II infusion and its role in myocyte and coronary vascular damage. Catecholamines 0-13 angiotensinogen Homo sapiens 34-40 7503249-3 1995 Furthermore, it is unknown if this ANG II-induced catecholamine release is ANG II type 1 (AT1) receptor mediated or whether the increase in serum catecholamines is responsible for the myocyte and coronary vascular damage seen within the first 3 days of chronic ANG II infusion. Catecholamines 50-63 angiotensinogen Homo sapiens 35-41 7867187-2 1995 BACKGROUND: Angiotensin II (Ang II) facilitates adrenergic neurotransmission in normotensive and hypertensive subjects, whereas angiotensin-converting enzyme inhibitors have been shown to depress circulating catecholamine concentrations in some studies. Catecholamines 208-221 angiotensinogen Homo sapiens 28-34 7867187-2 1995 BACKGROUND: Angiotensin II (Ang II) facilitates adrenergic neurotransmission in normotensive and hypertensive subjects, whereas angiotensin-converting enzyme inhibitors have been shown to depress circulating catecholamine concentrations in some studies. Catecholamines 208-221 angiotensinogen Homo sapiens 12-26 7507911-3 1993 Here we briefly review the mechanisms by which one such agent (the neuropeptide substance P) modulates the cholinergic secretory response of adrenal chromaffin cells, and another agent (angiotensin II) elicits catecholamine secretion independently of the cholinergic innervation. Catecholamines 210-223 angiotensinogen Homo sapiens 186-200 35072084-0 2022 Effectiveness of Angiotensin II for Catecholamine Refractory Septic or Distributive Shock on Mortality: A Propensity Score Weighted Analysis of Real-World Experience in the Medical ICU. Catecholamines 36-49 angiotensinogen Homo sapiens 17-31 34614428-2 2021 Angiotensin II causes constriction of arterioles and venules, inhibits the reuptake of norepinephrine, stimulates the release of catecholamines, and hypertrophy of vascular smooth muscle cells. Catecholamines 129-143 angiotensinogen Homo sapiens 0-14 1290617-4 1992 The losartan-sensitive sites have been shown to mediate all of the major ANG II-induced biologic effects, including vasoconstriction, aldosterone and catecholamine release, and central, ANG II-induced drinking behavior. Catecholamines 150-163 angiotensinogen Homo sapiens 73-79 34597810-7 2021 However, intravenous angiotensin II in catecholamine-resistant septic shock patients showed substantial evidence of raising the MAP to target hemodynamic levels, thus allowing time to treat underlying conditions. Catecholamines 39-52 angiotensinogen Homo sapiens 21-35 2441195-7 1987 Angiotensin II mediated vasoconstriction perhaps enhanced by catecholamines could have deleterious effects on myocardial function and perfusion, and indicates the potential for angiotensin-converting enzyme inhibitors in early AMI. Catecholamines 61-75 angiotensinogen Homo sapiens 0-14 2833536-6 1988 In view of the known interactions of angiotensin II with both central and peripheral catecholamine-containing neurons of laboratory animals, the current anatomical findings suggest similar interactions between these neuroactive compounds in the human central nervous system. Catecholamines 85-98 angiotensinogen Homo sapiens 37-51 3035894-6 1987 Thus, in addition to its recognized modulatory effects in the peripheral adrenergic system, angiotensin II may be involved in the central control of catecholamine release and action. Catecholamines 149-162 angiotensinogen Homo sapiens 92-106 3038326-1 1987 Recent experimental studies showed that inhibition of angiotensin II synthesis may reduce sympathetic activity as evaluated by plasma catecholamine assay, sharing in the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors. Catecholamines 134-147 angiotensinogen Homo sapiens 54-68 3035894-3 1987 In the adrenal gland, angiotensin II receptors are abundant in the zona glomerulosa but are also present in the medulla, where the occurrence of CRF receptors and actions on catecholamine release reveals an additional site at which the two peptides exert related actions, in this case in the peripheral neuroendocrine system. Catecholamines 174-187 angiotensinogen Homo sapiens 22-36 3691412-5 1987 The results demonstrate that (1) reactivity to angiotensin II, serotonin, epinephrine, and acute hypoxia is decreased during pregnancy, while the response to norepinephrine remain unchanged, (2) drug sensitivity is unchanged with serotonin and the catecholamines, increased with histamine, and decreased with angiotensin II, and (3) the responses to acute hypoxia and histamine have significant gender-related differences in reactivity independent of the changes observed during pregnancy. Catecholamines 248-262 angiotensinogen Homo sapiens 47-61 3023395-13 1986 In addition, angiotensin II increased and TPA inhibited catecholamine-stimulated inositol phosphate release. Catecholamines 56-69 angiotensinogen Homo sapiens 13-27 6375223-5 1984 Angiotensin II was positively correlated with pulmonary wedge pressure, urea and catecholamines and negatively correlated with cardiac output and natremia. Catecholamines 81-95 angiotensinogen Homo sapiens 0-14 3087578-1 1986 6-Hydroxydopamine-induced catecholamine denervations in the organum vasculosum of the lamina terminalis and the median preoptic nucleus attenuate drinking responses to systemic angiotensin II (ANG II) injections. Catecholamines 26-39 angiotensinogen Homo sapiens 177-191 3087578-1 1986 6-Hydroxydopamine-induced catecholamine denervations in the organum vasculosum of the lamina terminalis and the median preoptic nucleus attenuate drinking responses to systemic angiotensin II (ANG II) injections. Catecholamines 26-39 angiotensinogen Homo sapiens 193-199 3087578-2 1986 Transplanting catecholamines in these nuclei using fetal noradrenergic (NE) cell suspension restores ANG II-elicited thirst. Catecholamines 14-28 angiotensinogen Homo sapiens 101-107 4036531-8 1985 Therapeutic approaches to the treatment of catecholamine-induced heart failure may be potassium and magnesium supplements and possibly drugs reducing circulating angiotensin II activities. Catecholamines 43-56 angiotensinogen Homo sapiens 162-176 6870306-2 1983 In an attempt to enhance effects of cancer chemotherapy, Angiotensin II (AT), a vasoconstricting catecholamine, was applied to intra-arterial infusion of the drug for advanced breast cancer. Catecholamines 97-110 angiotensinogen Homo sapiens 57-71 6117405-0 1981 Angiotensin II releases catecholamines in dogfish. Catecholamines 24-38 angiotensinogen Homo sapiens 0-14 6306616-3 1983 In the present study we examined the possibility that angiotensin II, acting in brain, modulates endorphin-induced catecholamine secretion. Catecholamines 115-128 angiotensinogen Homo sapiens 54-68 537272-0 1979 Effects of angiotensin II on the medullary neurons and their sensitivity to acetylcholine and catecholamines. Catecholamines 94-108 angiotensinogen Homo sapiens 11-25 7002344-5 1980 Intravenous infusion (0.4 microgram/kg per min) of an angiotensin II antagonist [Sar1, Ileu8]angiotensin II abolished the catecholamine response to intrarenal isoproterenol infusion. Catecholamines 122-135 angiotensinogen Homo sapiens 54-68 7002344-5 1980 Intravenous infusion (0.4 microgram/kg per min) of an angiotensin II antagonist [Sar1, Ileu8]angiotensin II abolished the catecholamine response to intrarenal isoproterenol infusion. Catecholamines 122-135 angiotensinogen Homo sapiens 93-107 729647-0 1978 Angiotensin II mediation of adrenal catecholamine secretion induced by intrarenal isoprenaline infusion. Catecholamines 36-49 angiotensinogen Homo sapiens 0-14 856615-4 1977 [Ile8]-angiotensin I blocked angiotensin II-induced catecholamine secretion and a pA2 value of 8.50 was obtained. Catecholamines 52-65 angiotensinogen Homo sapiens 29-43 1278551-1 1976 In experiments with perfusion of the renal vessels with isotonic saline solution, the ability of angiotensin-II to activate the smooth muscle cells of these vessels was shown: both by direct myotropic action and in an indirect way - by catecholamines. Catecholamines 236-250 angiotensinogen Homo sapiens 97-111 4332750-0 1971 Release of catecholamines during the induction of and recovery from tachyphylaxis to angiotensin II. Catecholamines 11-25 angiotensinogen Homo sapiens 85-99 4367898-0 1974 Inhibition of angiotensin-induced adrenal catecholamine release by 8-substituted analogs of angiotensin II. Catecholamines 42-55 angiotensinogen Homo sapiens 92-106 4328014-0 1971 Release of adrenal catecholamines by angiotensin I. Catecholamines 19-33 angiotensinogen Homo sapiens 37-50 32609011-0 2020 Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. Catecholamines 56-69 angiotensinogen Homo sapiens 37-51 4325764-1 1970 The actions of synthetic angiotensin II on adrenal and myocardial catecholamines. Catecholamines 66-80 angiotensinogen Homo sapiens 25-39 4305919-0 1968 [Studies on the effect of angiotensin II on catecholamine metabolism in man]. Catecholamines 44-57 angiotensinogen Homo sapiens 26-40 33231111-1 2022 INTRODUCTION: Angiotensin II (Ang-2) is a non-catecholamine vasopressor that targets the renin-angiotensin-aldosterone system by agonism of the angiotensin type 1 receptor. Catecholamines 46-59 angiotensinogen Homo sapiens 14-28 32609011-1 2020 RATIONALE: Exogenous angiotensin II increases mean arterial pressure in patients with catecholamine-resistant vasodilatory shock (CRVS). Catecholamines 86-99 angiotensinogen Homo sapiens 21-35 32868151-3 2021 Angiotensin II (ANG-2) is of increasing interest as an adjunct to traditional therapy, both for improvement in blood pressure and for sparing the use of high-dose catecholamine vasopressors. Catecholamines 163-176 angiotensinogen Homo sapiens 0-14 32931196-8 2020 Angiotensin II caused a significant increase in mean arterial pressure and a rapid reduction in catecholamine vasopressor doses from 0.75 to 0.31 mcg/kg/min norepinephrine equivalents. Catecholamines 96-109 angiotensinogen Homo sapiens 0-14 32931196-11 2020 CONCLUSION: Exogenous angiotensin II reduced catecholamine vasopressor doses and had an apparent effect in reducing endogenous renin production in this case. Catecholamines 45-58 angiotensinogen Homo sapiens 22-36 32909718-0 2020 Catecholamine-Sparing Effect of Angiotensin II in an Anephric Patient With Mixed Shock After Cardiac Revascularization Surgery: A Case Report. Catecholamines 0-13 angiotensinogen Homo sapiens 32-46 32251161-0 2020 A Patient With Tricyclic Antidepressant Overdose With Catecholamine-Resistant Hypotension Rescued With Angiotensin II: A Case Report. Catecholamines 54-67 angiotensinogen Homo sapiens 103-117 32251161-2 2020 The purpose of this case is to describe how the use of angiotensin II can improve hemodynamic parameters and result in a dose reduction of other catecholamine vasopressors in vasodilatory shock. Catecholamines 145-158 angiotensinogen Homo sapiens 55-69 30601161-7 2019 In this randomized, double-blind, placebo-controlled trial, patients in the angiotensin II group achieved higher rates of target mean arterial pressure and had lower catecholamine requirements in the first 3 hours of therapy compared with patients in the placebo group. Catecholamines 166-179 angiotensinogen Homo sapiens 76-90 32028998-0 2020 Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. Catecholamines 67-80 angiotensinogen Homo sapiens 18-32 32028998-2 2020 The objective of these protocol prespecified and subsequent post hoc analyses was to assess the epidemiology and outcome associations of plasma ANG I and ANG II levels and their ratio in patients with catecholamine-resistant vasodilatory shock (CRVS) enrolled in the Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) study. Catecholamines 201-214 angiotensinogen Homo sapiens 144-149 32166277-3 2019 Both patients had a significant increase in mean arterial pressure shortly after initiation of angiotensin II, with a reduction of the dose of catecholamines and vasopressin infusions. Catecholamines 143-157 angiotensinogen Homo sapiens 95-109 29688923-4 2018 After AT II initiation, there was an immediate reduction in catecholamine requirement, and the patient survived. Catecholamines 60-73 angiotensinogen Homo sapiens 6-11 30784606-1 2019 The Angiotensin II for the Treatment of Vasodilatory Shock (ATHOS-3) trial demonstrated the vasopressor effects and catecholamine-sparing properties of angiotensin II. Catecholamines 116-129 angiotensinogen Homo sapiens 4-18 30784606-1 2019 The Angiotensin II for the Treatment of Vasodilatory Shock (ATHOS-3) trial demonstrated the vasopressor effects and catecholamine-sparing properties of angiotensin II. Catecholamines 116-129 angiotensinogen Homo sapiens 152-166 29329694-8 2018 Novel vasopressor agents, such as synthetic human angiotensin II, can increase BP and reduce the need for high doses of catecholamine vasopressors in severe or refractory vasodilatory shock. Catecholamines 120-133 angiotensinogen Homo sapiens 50-64 29877879-3 2018 RECENT FINDINGS: The Angiotensin II for the Treatment of High-Output Shock 3 study evaluated angiotensin II use in patients with high-output, vasodilatory shock and demonstrated reduced background catecholamine doses and improved ability to achieve blood pressure goals associated with the use of angiotensin II. Catecholamines 197-210 angiotensinogen Homo sapiens 21-35 29877879-3 2018 RECENT FINDINGS: The Angiotensin II for the Treatment of High-Output Shock 3 study evaluated angiotensin II use in patients with high-output, vasodilatory shock and demonstrated reduced background catecholamine doses and improved ability to achieve blood pressure goals associated with the use of angiotensin II. Catecholamines 197-210 angiotensinogen Homo sapiens 93-107 25286986-2 2014 Angiotensin II (ATII) may prove useful in patients who remain hypotensive despite catecholamine and vasopressin therapy. Catecholamines 82-95 angiotensinogen Homo sapiens 0-14 27879559-3 2017 Angiotensin II (Ang II), a key product of the renin-angiotensin-aldosterone system, is a vasopressor agent that could be used in conjunction with other vasopressors to stabilize critically ill patients during refractory septic shock, and reduce catecholamine requirements. Catecholamines 245-258 angiotensinogen Homo sapiens 0-14 27879559-3 2017 Angiotensin II (Ang II), a key product of the renin-angiotensin-aldosterone system, is a vasopressor agent that could be used in conjunction with other vasopressors to stabilize critically ill patients during refractory septic shock, and reduce catecholamine requirements. Catecholamines 245-258 angiotensinogen Homo sapiens 16-22 26931475-7 2016 Recently, a phase 3 trial using infused angiotensin II (LJPC-501) as treatment option in catecholamine-resistent hypotension was established (ClinicalTrials.gov identifier NCT02338843) although it might be that an influence of AngII-derived peptides is not considered. Catecholamines 89-102 angiotensinogen Homo sapiens 40-54 18593382-6 2008 Catecholamines and peptide hormones, such as AngII (angiotensin II), are elevated in hypertension and, therefore, signalling by these GPCRs is increased. Catecholamines 0-14 angiotensinogen Homo sapiens 45-50 18593382-6 2008 Catecholamines and peptide hormones, such as AngII (angiotensin II), are elevated in hypertension and, therefore, signalling by these GPCRs is increased. Catecholamines 0-14 angiotensinogen Homo sapiens 52-66